Dear Label_Name,

Greetings! I hope you are well.

I am writing on behalf of an international publishing house, Science and Education Publishing, USA (http://www.sciepub.com).

Science and Education Publishing (SciEP) is a multidisciplinary open access publisher of Journals covering the fields of Science, Technology and Medicine. All SciEP publications are subject to high-quality peer review, editorial and production processes and are freely available online.

Welcome to the April, 2013 edition of SciEP newsletter, providing monthly summaries of articles on science & education related topics of interest to scientist and professionals. The mission of our journals is to provide an open access forum for publishing new findings on issues pertinent to scientific and academic field. We also invite you to submit original research papers, review articles, short reports, or case studies are considered for publication in our Multidisciplinary Journals.

American Journal of Public Health Research
DOI: 10.12691/ajphr-1-1-3

The Implementation of a Tele-Homecare System with Service Oriented Architecture and HL7 Message Transmission Standard
Ching-Sung Wang

American Journal of Medical and Biological Research
DOI: 10.12691/ajmbr-1-1-2

The Influence of Ethanol on Pyruvate Kinases Activity in Vivo, in Vitro, in Silico
Lelevich Sergey Vladimirovich, Khrustalev Vladislav Victorovich, Barkovsky Eugene Victorovich, Shedogubova Tatyana Aleksandrovna

American Journal of Medical Sciences and Medicine
DOI: 10.12691/ajmsm-1-1-1

Clinical and Histological Features in Wegener Granulomatosis
Li Cavoli Gioacchino, Passantino Rita, Bono Luisa, Tortorici Calogera, Ferrantelli Angelo, Giammarresi Carlo, Rotolo Ugo

American Journal of Infectious Diseases and Microbiology
DOI: 10.12691/ajidm-1-1-2

The Curse of Lymphatic Filariasis: Would the Continual Use of Diethylcarbamazine Eliminate this Scourge in Papua New Guinea?
Anne Lanham, Lillian Mwanri

We have released issues of some journals on February 2013.
American Journal of Public Health Research
American Journal of Medical Sciences and Medicine
American Journal of Medical and Biological Research
American Journal of Pharmacological Sciences
American Journal of Clinical Medicine Research
American Journal of Nursing Research
American Journal of Cancer Prevention
American Journal of Medicine Studies
American Journal of Infectious Diseases and Microbiology
American Journal of Cardiovascular Disease Research
American Journal of Biomedical Research
American Journal of Mechanical Engineering
American Journal of Microbiological Research
Journal of Preventive Medicine
American Journal of Food and Nutrition
American Journal of Hypertension Research
American Journal of Sports Science and Medicine
Journal of Cancer Research and Treatment
American Journal of Zoological Research
Journal of Biomedical Engineering and Technology
American Journal of Microbiological Research
Biomedical Science and Engineering

We are pleased to announce that submissions are now being accepted for peer review for all the journals across all our subject areas in SciEP.

Please submit your manuscript via our online submission system:
http://www.sciepub.com/author/signin

To unsubscribe from our mailing list, please click on the following link: unsubscribe

I am looking forward to hearing from you.

Kind regards,

David Rain
Email:join@sciepub.com
Science and Education Publishing (http://www.sciepub.com)

Cerebral Venous Sinus Thrombosis without Thrombotic Thrombocytopenic Syndrome in a Male Patient after Ad26.COV2.S Vaccination

Kara L Heuvelhorst, Tyler Diener, Hana Manzoor*, Maher Khadra, Faisal Musa, Syed K Jafri

Departments of Radiology and Hematology-Oncology, Beaumont Hospital Dearborn, 18101 Oakwood Blvd, Dearborn, MI 48124

Abstract: Objective: Here we present one of the first cases of Janssen (Johnson & Johnson Ad26.COV2.S vaccine-associated cerebral venous sinus thrombosis (CVST) in a male patient, and the presumed first case without associated thrombotic thrombocytopenic syndrome (TTS). Method: Patient was identified as a vaccine-related adverse effect due to the unusual presentation of CVST in a male following COVID-19 vaccination, though without thrombocytopenia. Results: Patient presented with left-sided weakness and transient dysarthria. Imaging revealed extensive CVST. Thorough coagulopathy work-up was negative and platelet levels remained within the normal range. Patient improved with non-heparin anticoagulation. Discussion: As more people worldwide continue to be vaccinated against COVID-19, the incidence of vaccine-related complications can be expected to rise. Multiple cases of CVST have been reported in patients following COVID-19 vaccination with associated TTS, nearly all in women. However, this is not the only presentation. Cerebral venous sinus thrombosis should be a consideration in patients who present with headache or altered mental status after COVID vaccination, despite normal platelet levels.

Keywords: Cerebral Venous Sinus Thrombosis, Vaccine, Johnson & Johnson, Janssen, AstraZeneca, Clot, COVID-19, FDA, CDC, anti-PF4, Thrombotic Thrombocytopenic Syndrome, Ad26.COV2.S

Received August 08, 2021; Revised September 16, 2021; Accepted September 25, 2021

Citation: Kara L Heuvelhorst, Tyler Diener, Hana Manzoor, Maher Khadra, Faisal Musa, Syed K Jafri, Cerebral Venous Sinus Thrombosis without Thrombotic Thrombocytopenic Syndrome in a Male Patient after Ad26.COV2.S Vaccination. American Journal of Medical Case Reports, 9 (12). 719-721. January 2021. doi:10.12691/ajmcr-9-12-15

1. Case

A 59 year old male presented to the emergency department on April 27, 2021 with left upper and lower extremity weakness and transient dysarthria. The patient had no history of stroke, coagulopathy, immobilization, family history or other risk factors. Physical exam confirmed left-sided weakness. The patient received the Janssen vaccine on March 20, 2021, not known at the time of presentation. The stroke protocol was activated and the patient underwent a non-contrast enhanced CT head, which demonstrated asymmetric hyperdensity within the left transverse sinus and confluence of sinuses, as well as a small right frontal subarachnoid hemorrhage (Figure 1). Subsequent CT angiography and MRI Brain confirmed extensive cerebral sinus thrombosis involving the posterior portion of the sagittal sinus and bilateral transverse sinuses with suspected extension into the left sigmoid sinus (Figure 2).

The patient was admitted to the intensive care unit and initially started on intravenous heparin. This was promptly exchanged for argatroban when the team became aware of recent vaccine administration in an effort to prevent the feared complication of Heparin-induced Thrombocytopenia (HIT). Platelet levels upon arrival were within the normal range, and, although they declined slightly during his hospitalization, remained within the normal range throughout the admission. Interestingly, thorough hematologic workup revealed a negative result for the Heparin Platelet Factor 4 antibody (anti-PF4) and Serotonin Release Assay. Antiphospholipid antibody, Factor V and Protein C and S activity were also within normal limits. D-dimer was elevated at 1,123 ng/mL. A negative COVID-19 test was also confirmed using the polymerase chain reaction method.

The patient continued to improve with anticoagulation and was discharged on a 3 month course of oral apixaban. A thorough workup is still in progress to exclude alternative etiologies to explain the hypercoagulable state, including malignancy.

Figure 1. A, Unenhanced CT scan of head demonstrates subarachnoid hemorrhage in right frontal sulci (arrow). B, Unenhanced CT demonstrates hyperdense left transverse sinus (arrow). C, Coronal reformation of CT again demonstrates the hyperdense left transverse sinus (arrow).

Figure 2. A, CT Angiogram demonstrates extensive filling defects (arrows) within the superior sagittal sinus. B, MRI Brain with contrast confirms the findings

2. Discussion

The Janssen COVID-19 vaccine (Johnson & Johnson, Ad26.COV2.S) received emergency use authorization on February 27, 2021 [1,2]. Over the proceeding weeks, several cases of CVST with TTS were reported, nearly all in women under the age of 50 years old [1,2,3,4,5]. The use of the Janssen vaccine was temporarily suspended from April 13-21 while these cases were under investigation [6]. The CDC and FDA have since recommended resuming use of the vaccine with a warning for women younger than 50 years old [6,7].

Several hospitalizations and a small number of deaths have been reported related to CVST with TTS associated with the Janssen and AtraZeneca (ChAdOx1 nCoV-19) vaccines, the vast majority in female patients less than 50 years of age [1,2,6,8]. It appears that of those tested, all were positive for the presence of heparin-platelet factor 4 HIT antibody (anti-PF4) [1,2,4,5,8,9,10] via enzyme-linked immunosorbent assay (ELISA). Our patient, however, tested negative for anti-PF4. To our knowledge, this is the first reported case of Janssen vaccine-associated cerebral venous sinus thrombosis without thrombotic thrombocytopenia syndrome.

As the number of patients who receive COVID-19 vaccines increases worldwide, there should be a continued high index of suspicion for CVST in patients who present with headache or altered mental status after administration [1], despite normal platelet levels.

Written informed consent for publication of their clinical details and/or clinical images was obtained from the patient. A copy of the consent form is available for review by the Editor of this journal.

Abbreviations

FDA, Food and Drug Administration; CVST, Cerebral Venous Sinus Thrombosis; TTS, Thrombotic 1Thrombocytopenia Syndrome; DVT, Deep Venous Thrombosis; CDC, Centers for Disease Control; Anti-PF4, Platelet Factor 4 antibody; HIT, Heparin-induced Thrombocytopenia

Acknowledgements

John Kim, MD

Declarations of Interest

No relevant relationships.

References

[1]  
Tom Shimabukuro, CDC COVID-19 Vaccine Task Force, Vaccine Safety Team, Advisory Committee on Immunization Practices (ACIP), National Center for Immunization & Respiratory Diseases. Reports of Cerebral Venous Sinus Thrombosis with Thrombocytopenia after Janssen COVID-19 Vaccine.; 2021. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-04/03-COVID-Shimabukuro-508.pdf.

[2]   | See I, Su JR, Lale A, et al. US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination, March 2 to April 21, 2021. JAMA. Published online 2021.
[3]   | Health Alert Network (distributed via Centers for Disease Control and Prevention). Cases of Cerebral Venous Sinus Thrombosis with Thrombocytopenia after Receipt of the Johnson & Johnson COVID-19 Vaccine (CDCHAN-00442). 2021. https://emergency.cdc.gov/han/2021/han00442.asp.
[4]   | Greinacher A, Selleng K, Wesche J, et al. Towards Understanding ChAdOx1 nCov-19 Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT). Research Square. Published online 2021.
[5]   | Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021; (NEJMoa2104840).

[6]  
Office of the Commissioner. FDA and CDC lift recommended pause on Johnson & Johnson (Janssen) COVID-19 Vaccine use following thorough safety review. Fda.gov. Published 2021. Accessed May 28, 2021. https://www.fda.gov/news-events/press-announcements/fda-and-cdc-lift-recommended-pause-johnson-johnson-janssen-covid-19-vaccine-use-following-thorough.

[7]   | CDC. CDC recommends use of Johnson & Johnson’s Janssen COVID-19 vaccine resume. Cdc.gov. Published May 18, 2021. Accessed May 28, 2021. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/JJUpdate.html.
[8]   | Cines DB, Bussel JB. SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia. N Engl J Med. 2021; (NEJMe2106315).
[9]   | Scully M, Singh D, Lown R, et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021; (NEJMoa2105385).
[10]   | Schultz NH, Sørvoll IH, Michelsen AE, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021; (NEJMoa2104882).